JP2019519215A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519215A5
JP2019519215A5 JP2018560491A JP2018560491A JP2019519215A5 JP 2019519215 A5 JP2019519215 A5 JP 2019519215A5 JP 2018560491 A JP2018560491 A JP 2018560491A JP 2018560491 A JP2018560491 A JP 2018560491A JP 2019519215 A5 JP2019519215 A5 JP 2019519215A5
Authority
JP
Japan
Prior art keywords
fusion protein
cell
cells
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560491A
Other languages
English (en)
Japanese (ja)
Other versions
JP7178906B2 (ja
JP2019519215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033585 external-priority patent/WO2017201432A2/en
Publication of JP2019519215A publication Critical patent/JP2019519215A/ja
Publication of JP2019519215A5 publication Critical patent/JP2019519215A5/ja
Application granted granted Critical
Publication of JP7178906B2 publication Critical patent/JP7178906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560491A 2016-05-19 2017-05-19 ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ Active JP7178906B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662338757P 2016-05-19 2016-05-19
US62/338,757 2016-05-19
US201762471456P 2017-03-15 2017-03-15
US62/471,456 2017-03-15
PCT/US2017/033585 WO2017201432A2 (en) 2016-05-19 2017-05-19 Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity

Publications (3)

Publication Number Publication Date
JP2019519215A JP2019519215A (ja) 2019-07-11
JP2019519215A5 true JP2019519215A5 (enExample) 2020-07-02
JP7178906B2 JP7178906B2 (ja) 2022-11-28

Family

ID=60326626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560491A Active JP7178906B2 (ja) 2016-05-19 2017-05-19 ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２

Country Status (5)

Country Link
US (1) US12202856B2 (enExample)
EP (1) EP3458485B1 (enExample)
JP (1) JP7178906B2 (enExample)
CN (1) CN109689694B (enExample)
WO (1) WO2017201432A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3768700A1 (en) * 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
KR102824112B1 (ko) * 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
CN112262214A (zh) * 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
AU2020329216A1 (en) * 2019-08-12 2022-02-24 AskGene Pharma, Inc. IL-2 fusion proteins that preferentially bind ILl-2ralpha
US11414852B2 (en) * 2019-09-22 2022-08-16 Bio Clean Environmental Services, Inc. Removable trash filter basket with hinged wier for catch basins
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP7767290B2 (ja) 2020-01-11 2025-11-11 アスクジーン・ファーマ・インコーポレイテッド 新規なマスクされたサイトカインおよびその使用方法
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
US20230159892A1 (en) * 2020-04-06 2023-05-25 Synthekine, Inc. Engineered immune cells
CN112266413A (zh) * 2020-10-22 2021-01-26 中国人民解放军海军军医大学 扩增nk细胞并增强其杀伤活性的因子、饲养细胞系及方法
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022232796A1 (en) * 2021-04-28 2022-11-03 The General Hospital Corporation Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
CA3260691A1 (en) * 2022-08-26 2024-02-29 Sonoma Biotherapeutics, Inc. Attached Recombinant Interleukin-2 Receptors and Methods of Use
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
TW202436337A (zh) 2023-01-23 2024-09-16 漢諾威醫學院 嵌合抗原受體
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4669343A1 (en) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover CHIMERIC ANTIGEN RECIPIENT
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2025090939A1 (en) * 2023-10-26 2025-05-01 The General Hospital Corporation Self-activating il15 chimeric cytokine receptors
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022914A1 (en) * 1993-04-06 1994-10-13 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP1690927A1 (en) 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE60035057T2 (de) 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
JP2007506789A (ja) 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CN100379762C (zh) * 2003-12-08 2008-04-09 中国人民解放军军事医学科学院生物工程研究所 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
KR101223373B1 (ko) 2003-12-25 2013-01-16 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
US7674621B2 (en) 2004-05-21 2010-03-09 The United States Of America As Represented By The Department Of Health And Human Services Plasmids and phages for homologous recombination and methods of use
PL2921500T3 (pl) 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
US20080280781A1 (en) 2005-01-16 2008-11-13 Georgia Tech Research Corporation Methods and Compositions for Increasing Membrane Permeability
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
AU2007275689A1 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. AZA-peptide protease inhibitors
US20090025274A1 (en) 2007-07-23 2009-01-29 Tim Lail Animal trap
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
NZ602020A (en) 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JP5458188B2 (ja) 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
AU2014214850C1 (en) 2013-02-06 2018-12-06 Celgene Corporation Modified T lymphocytes having improved specificity
CN105658206A (zh) 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
CN106459916A (zh) 2014-06-18 2017-02-22 乔治-施派尔-豪斯化学疗法研究所 作为细胞治疗剂的car‑表达nk‑92细胞
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
ES2763548T3 (es) 2014-11-06 2020-05-29 Hoffmann La Roche Anticuerpos anti-TIM3 y procedimientos de uso
US10336810B2 (en) * 2015-02-12 2019-07-02 University Health Network Chimeric antigen receptors, encoding nucleic acids and methods of use thereof
CN107922484A (zh) 2015-03-06 2018-04-17 索伦托治疗有限公司 结合tim3的抗体治疗剂
KR102751730B1 (ko) 2015-03-27 2025-01-10 이뮤너티바이오, 인크. 암의 치료를 위한 유전적으로 변형된 nk-92 세포 및 모노클로날 항체
KR20180004740A (ko) 2015-04-20 2018-01-12 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
CN114853891A (zh) 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
DK3356411T3 (da) 2015-10-02 2021-09-06 Hoffmann La Roche Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US20190127435A1 (en) * 2016-04-20 2019-05-02 Fred Hutchinson Cancer Research Center Immunomodulatory il2r fusion proteins and uses thereof
UA127200C2 (uk) 2016-05-18 2023-06-07 Бьорінгер Інгельхайм Інтернаціональ Гмбх Молекула антитіла до pd1
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JP2020510422A (ja) 2017-02-28 2020-04-09 シアトル ジェネティックス， インコーポレイテッド 抗ｔｉｇｉｔ抗体
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
US12385061B2 (en) 2017-09-08 2025-08-12 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
WO2022232796A1 (en) 2021-04-28 2022-11-03 The General Hospital Corporation Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity

Similar Documents

Publication Publication Date Title
Maggs et al. CAR T cell-based immunotherapy for the treatment of glioblastoma
Duan et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma
Suarez et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
JP2021040652A (ja) Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2020040969A5 (enExample)
JP2018529363A5 (enExample)
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2020508329A5 (enExample)
JP2017538401A5 (enExample)
JP2019520591A5 (enExample)
JP2016520074A5 (enExample)
IL258029B (en) Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins
JP2018514204A (ja) ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞
CN107082812A (zh) 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
Annesley et al. The evolution and future of CAR T cells for B‐cell acute lymphoblastic leukemia
JP2016530889A (ja) Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド
CN107922489A (zh) κ骨髓瘤抗原嵌合性抗原受体和其用途
Jin et al. Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6
WO2016180034A1 (zh) 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
US20200270574A1 (en) CD1d and TCR-NKT Cells
JP2019530441A5 (enExample)
US20240424096A1 (en) IL-10 Expressing Cells For Enhanced Cancer Immunotherapies
US12473346B2 (en) A2/NY-ESO-1 specific t cell receptors and uses thereof
WO2019136273A1 (en) Reprogrammed t cell-like nk cells